Market Research Logo

Cystic Fibrosis Global Clinical Trials Review, H2, 2017

Cystic Fibrosis Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, “Cystic Fibrosis Global Clinical Trials Review, H2, 2017 provides an overview of Cystic Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table figure 1: Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2017*
    • Table Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region, 2017*
    • Clinical Trials and Average Enrollment by Country
      • Table figure 2: Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
      • Table Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
      • Table figure 3: Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
      • Table Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
    • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Table figure 4: Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
      • Table Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
    • Top Five Countries Contributing to Clinical Trials in Europe
      • Table figure 5: Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
      • Table Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
    • Top Countries Contributing to Clinical Trials in North America
      • Table figure 6: Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
      • Table Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2017*
    • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Table figure 7: Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
      • Table Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
    • Top Five Countries Contributing to Clinical Trials in Central and South America
      • Table figure 8: Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
      • Table Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
  • Clinical Trials by G7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials
    • Table figure 9: Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017*
    • Table Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017*
  • Clinical Trials by Phase in G7 Countries
    • Table figure 10: Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
    • Table Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Clinical Trials in G7 Countries by Trial Status
    • Table figure 11: Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
    • Table Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by E7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials
    • Table figure 12: Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017*
    • Table Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017*
  • Clinical Trials by Phase in E7 Countries
    • Table figure 13: Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
    • Table Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Clinical Trials in E7 Countries by Trial Status
    • Table figure 14: Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
    • Table Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by Phase
    • Table figure 15: Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2017*
    • Table Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2017*
    • In Progress Trials by Phase
      • Table figure 16: Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
      • Table Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Clinical Trials by Trial Status
    • Table figure 17: Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017*
    • Table Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by End Point Status
    • Table figure 18: Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017*
    • Table Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Subjects Recruited Over a Period of Time
    • Table figure 19: Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
    • Table Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Clinical Trials by Sponsor Type
    • Table figure 20: Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
    • Table Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Prominent Sponsors
    • Table figure 21: Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
    • Table Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
    • Top Companies Participating in Cystic Fibrosis Therapeutics Clinical Trials
      • Table figure 22: Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
      • Table Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Prominent Drugs
    • Table figure 23: Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
    • Table Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • Latest Clinical Trials News on Cystic Fibrosis
    • Jul 12, 2017: Synspiras Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis
    • Jul 10, 2017: Anthera Pharmaceuticals Announces Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network
    • Jun 29, 2017: Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis
    • Jun 20, 2017: Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference
    • Jun 13, 2017: Pharmaxis Announces Results of Pivotal Bronchitol Cystic Fibrosis Clinical Trial for US Market
    • Jun 09, 2017: Vertex Announces Nine Presentations of Data on ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) at the European Cystic Fibrosis Society Conference
    • Jun 08, 2017: Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
    • Jun 08, 2017: Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference
    • Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
    • Jun 07, 2017: Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference
    • Jun 07, 2017: Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs
    • Jun 07, 2017: Proteostasis Therapeutics Announces Update on Phase 1 Trial of PTI-808, CFTR potentiator
    • Jun 07, 2017: Proteostasis Therapeutics Announces Clinical Development Update on Cystic Fibrosis Drug Candidate PTI-801
    • Jun 05, 2017: Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA
    • Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis
    • May 24, 2017: Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference
    • May 23, 2017: Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
    • May 17, 2017: Celtaxsys Announces Full Enrollment of Its Landmark EMPIRE-CF Phase 2b Clinical Trial Assessing the Potential of Novel Anti-inflammatory Investigational Therapy, Oral Acebilustat, to Preserve Lung Function in CF Patients
    • May 16, 2017: Spyryx Biosciences to Present at American Thoracic Society International Conference May 19- 24, 2017, Washington, DC
    • Apr 19, 2017: Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b for the Treatment of Cystic Fibrosis
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report